Monastyrskyi, Andrii; Nilchan, Napon; Quereda, Victor; Noguchi, Yoshihiko; Ruiz, Claudia; Grant, Wayne; Cameron, Michael; Duckett, Derek; Roush, William published the artcile< Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer>, Recommanded Product: 2,6-Dichloro-9-methyl-9H-purine, the main research area is casein kinase 1delta 1epsilon inhibitor antitumor breast purine preparation; Breast cancer; Casein kinase 1 delta and epsilon; Inhibitor; Kinase; Structure-activity relationship.
Casein kinase 1δ/ε have been identified as promising therapeutic target for oncol. application, including breast and brain cancer. Here, the authors described the authors’ continued efforts in optimization of a lead series of purine scaffold inhibitors that led to identification of two new CK1δ/ε inhibitors 17 (N-((4,5-Difluoro-1H-benzo[d]imidazol-2-yl)methyl)-9-(3,5-difluorophenyl)-2-morpholino-9H-purin-6-amine) and 28 (N-((4,5-Difluoro-1H-benzo[d]imidazol-2-yl)methyl)-2-(4-methylpiperazin-1-yl)-9-(pyridin-4-yl)-9H-purin-6-amine) displaying low nanomolar values in antiproliferative assays against the human MDA-MB-231 triple neg. breast cancer cell line and have phys., in vitro and in vivo pharmacokinetic properties suitable for use in proof of principle animal xenograft studies against human cancers.
Bioorganic & Medicinal Chemistry published new progress about Antiproliferative agents. 2382-10-7 belongs to class chlorides-buliding-blocks, and the molecular formula is C6H4Cl2N4, Recommanded Product: 2,6-Dichloro-9-methyl-9H-purine.
Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics